Danaher (NYSE:DHR) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share guidance of – for the period. The company issued revenue guidance of $6.82 billion-$6.82 billion, compared to the consensus revenue estimate of $6.13 billion.
NYSE DHR traded up $1.36 on Tuesday, reaching $256.03. The company’s stock had a trading volume of 2,000,446 shares, compared to its average volume of 2,591,197. Danaher has a twelve month low of $155.61 and a twelve month high of $260.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.68 and a current ratio of 2.08. The stock has a market cap of $182.62 billion, a PE ratio of 51.61, a PEG ratio of 1.92 and a beta of 0.72. The firm’s 50 day moving average is $234.48 and its two-hundred day moving average is $230.73.
Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, April 21st. The conglomerate reported $2.52 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.85. Danaher had a net margin of 18.05% and a return on equity of 12.94%. The company had revenue of $6.87 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the firm earned $1.05 earnings per share. The business’s quarterly revenue was up 58.2% on a year-over-year basis. Equities research analysts anticipate that Danaher will post 6.05 EPS for the current fiscal year.
A number of research firms have commented on DHR. Credit Suisse Group upped their price objective on shares of Danaher from $260.00 to $264.00 and gave the company an outperform rating in a research note on Thursday, January 14th. Citigroup upped their price objective on shares of Danaher from $275.00 to $315.00 in a research note on Friday, April 23rd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their target price on Danaher from $275.00 to $315.00 in a report on Friday, April 23rd. KeyCorp upped their target price on Danaher from $280.00 to $315.00 and gave the company an overweight rating in a report on Thursday, April 29th. Finally, Zacks Investment Research downgraded Danaher from a hold rating to a sell rating and set a $241.00 target price on the stock. in a report on Friday, April 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $265.63.
In other Danaher news, EVP Joakim Weidemanis sold 17,169 shares of the stock in a transaction that occurred on Tuesday, April 27th. The stock was sold at an average price of $258.76, for a total transaction of $4,442,650.44. Following the transaction, the executive vice president now owns 84,420 shares in the company, valued at $21,844,519.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Angela S. Lalor sold 3,092 shares of the stock in a transaction that occurred on Friday, April 23rd. The shares were sold at an average price of $255.79, for a total value of $790,902.68. Following the transaction, the senior vice president now owns 30,937 shares in the company, valued at approximately $7,913,375.23. The disclosure for this sale can be found here. Insiders sold 26,698 shares of company stock worth $6,808,687 in the last 90 days. 11.70% of the stock is currently owned by corporate insiders.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
See Also: What is the yield curve?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.